(ATNM) Actinium Pharmaceuticals, Inc. VRIO Analysis Research |
Fully Editable: Tailor To Your Needs In Excel Or Sheets
Professional Design: Trusted, Industry-Standard Templates
Investor-Approved Valuation Models
MAC/PC Compatible, Fully Unlocked
No Expertise Is Needed; Easy To Follow
(ATNM) Actinium Pharmaceuticals, Inc. Complete Analysis Pack
Actinium Pharmaceuticals VRIO: Uncover Its Competitive Edge
Unlock Actinium Pharmaceuticals, Inc.’s true strategic posture with the full VRIO Analysis—an actionable, company-specific assessment that shows which resources drive value, which are rare or hard to copy, and how well the firm is organized to capture advantage; ideal for investors, analysts, and strategists who need a clear roadmap to competitive strength.
Lead late-stage asset: Iomab-B
Value
Iomab-B (apamistamab) has strong Value in Actinium Pharmaceuticals, Inc.’s VRIO mix because its Phase III use case targets older relapsed/refractory AML patients before BMT, a niche with very few effective options. In AML, 5-year survival is about 31.7% overall and is far lower in older patients, so a transplant-enabling therapy addresses a clear unmet need.
Rarity
Iomab-B is rare because Actinium Pharmaceuticals, Inc. combines antibody-targeted radioimmunotherapy with a multi-isotope platform, while most small biopharma peers focus on one payload or one isotope. In 2025, Actinium Pharmaceuticals, Inc. reported no product revenue and continued to fund late-stage development, which underscores how unusual this capability is for a small-cap company.
Imitability
Targeting CD45 can be copied in theory, but Actinium Pharmaceuticals, Inc.'s Iomab-B is harder to match because the linker, dosing, and transplant-conditioning schedule are tuned from its SIERRA Phase 3 program, which enrolled 153 patients. That makes the construct easier to imitate on paper than to reproduce with the same safety and response profile in real use.
Organization
Iomab-B is Actinium Pharmaceuticals, Inc.'s core late-stage asset, and it keeps the company tightly focused on transplant conditioning rather than a wide oncology portfolio. That narrow scope can be a VRIO edge because the asset sits in a rare, hard-to-replicate niche with years of transplant know-how behind it.
The tradeoff is concentration risk: in Actinium Pharmaceuticals, Inc.'s 2025 filings, the business still depended on this single lead program, so its strategic value is high but not broadly diversified.
Competitive Advantage
Iomab-B gives Actinium Pharmaceuticals, Inc. a temporary edge because it is the lead late-stage CD45-targeted conditioning asset, and the SIERRA study enrolled 153 patients. But the moat is still narrow until FDA approval and real sales arrive, so rivals can close the gap fast.
Iomab-B Drives Actinium's Late-Stage Story
Iomab-B is Actinium Pharmaceuticals, Inc.'s key late-stage asset because it targets CD45 for transplant conditioning in relapsed/refractory AML, a niche with few options. The SIERRA Phase 3 trial enrolled 153 patients, and Actinium Pharmaceuticals, Inc. reported no product revenue in 2025, so the asset still drives most of the story.
| Metric | Data |
|---|---|
| Target | CD45 |
| Phase 3 size | 153 |
| 2025 product revenue | 0 |
What is included in the product
Detailed Word Document
Assesses Actinium Pharmaceuticals’ key resources and capabilities for value, rarity, imitability, and organizational strength.
Customizable Excel Spreadsheet
Quickly highlights Actinium’s strategic resources, competitive edge, and defensibility without building a VRIO from scratch.
Reference Sources
Shows which Actinium resources are valuable, rare, hard to imitate, and supported by the organization.
Radiopharmaceutical isotope platform
Value
Actinium Pharmaceuticals, Inc.'s radiopharmaceutical isotope platform has clear value because Phase III I-131 apamistamab is aimed at elderly relapsed/refractory AML patients before BMT, a setting with very few options and poor outcomes; in AML, 5-year relative survival is about 31%, and it falls sharply in older relapsed patients.
That makes the platform clinically meaningful and commercially focused: it targets a small, high-need niche where even modest response gains can matter a lot.
Rarity
Actinium Pharmaceuticals, Inc.'s multi-isotope radiopharmaceutical platform is rare among small biopharma peers because most focus on one isotope, while Actinium Pharmaceuticals, Inc. has built know-how around multiple payloads. Actinium Pharmaceuticals, Inc. reported about $30 million in cash and equivalents and no product revenue in its FY2025 filings, underscoring how unusual this breadth is for a company of its size.
Imitability
Target choice in Actinium Pharmaceuticals, Inc.'s radiopharmaceutical isotope platform can be copied, but the hard part is matching its construct design and dose timing. The SIERRA Phase 3 study for Iomab-B enrolled 153 patients, and that kind of clinical optimization is slower to duplicate than the target idea itself.
Organization
Actinium Pharmaceuticals, Inc. is organized around transplant-focused radiopharmaceutical development, not broad oncology sprawl, and that narrow scope makes its isotope platform more specialized and harder to copy. Its value comes from a concentrated pipeline built around one core disease path, with Iomab-B still the lead asset and a 2025 market cap far below large-cap oncology peers, which shows both scarcity and execution risk.
Competitive Advantage
Actinium Pharmaceuticals, Inc.’s radiopharmaceutical isotope platform can create a temporary competitive advantage because isotope supply, handling, and target-specific manufacturing are hard to copy fast. But the edge is not durable: the company still has no approved product, so the moat depends on execution, clinical data, and securing reliable isotope supply against better-funded rivals.
Actinium’s Isotope Platform Is a Rare Moat—For Now
Actinium Pharmaceuticals, Inc.'s radiopharmaceutical isotope platform is valuable because it backs Iomab-B and other targeted payloads for hard-to-treat AML, where choices are scarce and the SIERRA Phase 3 trial enrolled 153 patients. It is rare in a small biopharma, but the moat is only temporary because Actinium Pharmaceuticals, Inc. still had about $30 million in cash and no product revenue in FY2025.
| Metric | Actinium Pharmaceuticals, Inc. |
|---|---|
| Lead Phase 3 trial | SIERRA, 153 patients |
| Cash and equivalents | About $30 million |
| Product revenue | Zero in FY2025 |
Delivered as Displayed
VRIO Analysis
The document you're previewing is the actual Actinium Pharmaceuticals, Inc. VRIO Analysis—not a mockup or sample—and it mirrors exactly the file you’ll receive after purchase; upon ordering, you’ll download this same professional, editable document in its full form, formatted and ready to use.
Multi-target antibody-radio conjugate design capability
Value
Actinium Pharmaceuticals, Inc. adds real Value here because Phase III I-31 apamistamab is aimed at elderly relapsed/refractory AML patients before BMT, a small but severe niche with few good options. AML’s median age is about 68, and older patients still face poor survival, so a targeted antibody-radio conjugate can fill a clear clinical gap.
Rarity
Actinium Pharmaceuticals, Inc.’s ability to design antibody-radio conjugates across multiple isotopes is rare for a small biopharma company. Most peers focus on one isotope or one lead asset, so this wider technical base gives Actinium Pharmaceuticals, Inc. a clearer differentiation in R&D flexibility.
Imitability
Target choice can be copied, but Actinium Pharmaceuticals, Inc.’s real edge is harder to clone: the construct-level tuning of linker, payload ratio, and dose schedule for each multi-target antibody-radio conjugate. That is why the idea is easy to imitate, but the optimization path is not.
Organization
Actinium Pharmaceuticals, Inc. is built around a narrow transplant-focused model, with two lead clinical programs, Iomab-B and Actimab-A, instead of a broad oncology slate. That focus helps the organization keep its multi-target antibody-radio conjugate work aligned with one clear use case: conditioning and targeted delivery around stem cell transplant.
Competitive Advantage
Actinium Pharmaceuticals, Inc. has a temporary edge because its multi-target antibody-radio conjugate design can steer radiation to several tumor markers, but the moat is not hard to copy as rivals advance other radioconjugates. In 2025, the key proof point remained Iomab-B in Phase 3, so the value is real but still tied to clinical execution.
Actinium’s Iomab-B Edge: Tunable Radio-Conjugate Design for AML
Actinium Pharmaceuticals, Inc. has a narrow but useful edge in multi-target antibody-radio conjugate design: it can tune linker, payload, and dose across isotopes for transplant-focused cancer use. In 2025, that mattered most for Iomab-B, its Phase 3 lead in older relapsed/refractory AML before BMT.
| Metric | Actinium Pharmaceuticals, Inc. |
|---|---|
| Lead proof point | Iomab-B Phase 3 |
| Core use case | Pre-BMT AML conditioning |
| Design edge | Multi-isotope tuning |
| Moat | Hard to clone, easier to copy |
Bone marrow transplant and cell-therapy conditioning know-how
Value
Actinium Pharmaceuticals, Inc. has clear value here because Phase III I-31 apamistamab targets elderly relapsed/refractory AML before bone marrow transplant, a small but high-need group with few good options and poor survival. If it improves conditioning safety and transplant access, it could fill a real clinical gap in a market where even modest response gains can matter.
Rarity
Actinium Pharmaceuticals, Inc.’s bone marrow transplant and cell-therapy conditioning know-how is rare because it spans a broad multi-isotope platform, something few small biopharma peers can match. That breadth matters in a niche where the company’s clinical work centers on targeted conditioning, including Iomab-B and other ACD-linked programs, and where specialized isotope handling is a real entry barrier.
Imitability
Target choice can be copied, but Actinium Pharmaceuticals, Inc.’s conditioning know-how is harder to mimic because each construct and dose plan has to be tuned for a Phase 3 setting, not just picked. In bone marrow transplant and cell therapy, even small shifts in target, exposure, and timing can change toxicity and engraftment outcomes, so the moat sits in execution, not the target itself.
Organization
Actinium Pharmaceuticals, Inc. stays centered on transplant and cell-therapy conditioning, with 2 lead assets, Iomab-B and ATNM-400, aimed at bone marrow transplant use instead of broad oncology sprawl. That focused setup makes its know-how scarce and hard to copy because the value sits in transplant-specific clinical design, dosing, and workflow fit.
Competitive Advantage
Actinium Pharmaceuticals, Inc.’s bone marrow transplant and cell-therapy conditioning know-how can create a temporary competitive advantage because it is tied to hard-to-build clinical execution and regulatory experience, not just patents. In FY2025, the company still operated as a development-stage biotech with no commercial revenue, so the edge depends on speed in trials and partner adoption more than scale.
Actinium’s niche transplant edge is hard to copy, but still pre-revenue
Actinium Pharmaceuticals, Inc.'s bone marrow transplant and cell-therapy conditioning know-how is valuable and still hard to copy because it rests on niche clinical execution, dosing, and isotope handling in a small transplant market. In FY2025, the Company remained development-stage with no commercial revenue, so this edge depends on trial progress and adoption, not scale.
| FY2025 metric | Actinium Pharmaceuticals, Inc. |
|---|---|
| Commercial revenue | $0 |
| Lead conditioning assets | Iomab-B, ATNM-400 |
| Business stage | Development-stage |
Clinical data package from Phase III and Phase I studies
Value
Actinium Pharmaceuticals, Inc.'s Phase III I-31 apamistamab data has clear value because it targets older relapsed/refractory AML patients, a group with a median diagnosis age near 68 and very limited transplant options. In this high-unmet-need niche, a pre-BMT conditioning path with Phase III plus Phase I support can strengthen clinical credibility and support pricing power.
Rarity
Actinium Pharmaceuticals, Inc. has a rare clinical data package because it spans both Phase III and Phase I programs and uses more than one isotope platform. Broad multi-isotope capability is uncommon among small biopharma peers, so this gives the Company a harder-to-copy evidence base for its radiopharma strategy.
Imitability
The clinical data package is only partly imitable: the target can be copied, but Actinium Pharmaceuticals, Inc.'s Phase III and Phase I results are tied to hard-to-recreate choices in construct design and dose strategy. In SIERRA, Phase III randomized 153 patients, and that kind of linked efficacy, safety, and dosing history raises the barrier for fast copycats.
Organization
Actinium Pharmaceuticals, Inc. is focused on transplant use, not broad oncology sprawl: its lead package centers on Iomab-B, supported by the Phase III SIERRA study in 153 patients and Phase I work that helped define dosing and safety. That narrow clinical base can be a strength in VRIO terms because it concentrates know-how, data, and regulatory effort around one transplant path.
Competitive Advantage
Actinium Pharmaceuticals, Inc.'s 153-patient Phase III SIERRA dataset, paired with Phase I safety and response data, gives it a real but temporary edge because late-stage evidence is harder to build and faster to copy once published. That makes the clinical package valuable today, but not rare for long, since competitors can design similar studies and move on the same AML targets.
Actinium’s Iomab-B Data Package Builds a Stronger AML Edge
Actinium Pharmaceuticals, Inc.'s clinical data package is valuable because it combines Phase III SIERRA in 153 patients with Phase I dose and safety work, giving the Company a tighter evidence base around Iomab-B for older relapsed/refractory AML patients. The package is still only partly rare, since the core design can be copied, but the linked late-stage and early-stage data make fast imitation harder.
| Study | Key data |
|---|---|
| Phase III SIERRA | 153 patients |
| Phase I | Supports dose and safety |
| Target group | Older r/r AML |
Memorial Sloan Kettering partnership
Value
The Memorial Sloan Kettering partnership adds real value because it supports Actinium Pharmaceuticals, Inc. Phase III I-31 apamistamab in elderly relapsed/refractory AML patients before BMT, a group with a median AML age of 68 and very limited curative options.
That niche is clinically strong: if the therapy helps more patients reach transplant, it can address a high-unmet-need setting where even small gains matter.
Rarity
Actinium Pharmaceuticals, Inc.'s Memorial Sloan Kettering tie-up is rare because it spans 2 isotope classes, alpha and beta emitters, while most small radiopharma peers stay focused on one. That broader access can speed target testing and lowers the chance that the pipeline depends on a single isotope supply.
Imitability
The Memorial Sloan Kettering partnership is only partly imitable: rivals can copy the target choice, but they cannot easily match the construct tuning, dosing schedule, and clinical know-how built with a top cancer center like Memorial Sloan Kettering. That tacit optimization is the real barrier, not the target itself.
Organization
Actinium Pharmaceuticals, Inc.'s Memorial Sloan Kettering partnership fits a narrow transplant-first model: it concentrates on conditioning and targeted hematology assets, not broad oncology sprawl. That focus can be a VRIO edge because Memorial Sloan Kettering's research and clinical network helps validate a pipeline where Actinium reported no product revenue in 2025 and only $0.6 million in collaboration revenue in 2024.
Competitive Advantage
Actinium Pharmaceuticals, Inc.'s Memorial Sloan Kettering tie-up gives fast clinical credibility and access to top oncology talent, which supports a temporary competitive advantage. But the edge is not durable: academic-center partnerships can be copied, and once trial data is public, rivals can match the signal with their own KOL networks and capital.
MSK Gives Actinium Rare AML Radiopharma Credibility
Memorial Sloan Kettering gives Actinium Pharmaceuticals, Inc. scarce clinical credibility in targeted radiopharma, especially for apamistamab in elderly relapsed/refractory AML before transplant. The partnership is hard to copy because it combines trial know-how, isotope access, and transplant-center validation, but the edge is still time-limited once data are public.
| Metric | Value |
|---|---|
| 2025 product revenue | 0 |
| 2024 collaboration revenue | $0.6M |
| Key use case | AML pre-BMT |
Multi-partner collaboration network
Value
Actinium Pharmaceuticals, Inc.'s Phase III Iomab-B (I-131 apamistamab) targets older relapsed/refractory AML patients before BMT, a small but high-value niche where standard salvage outcomes are poor and transplant access is limited. The collaboration network matters because it supports trial execution across specialized centers, helping Actinium Pharmaceuticals, Inc. reach a defined market with clear clinical need.
Rarity
Actinium Pharmaceuticals, Inc. sits in a rare spot: most small biopharma peers do not have a broad multi-isotope network, while Actinium Pharmaceuticals, Inc. has built a platform around targeted radiotherapies with more than one isotope path. That breadth matters because it supports 2 lead clinical assets, Iomab-B and Actimab-A, and makes partner-fit harder to copy.
Imitability
Target choice can be copied, but Actinium Pharmaceuticals, Inc.'s edge is harder to mirror: the exact construct design, payload mix, and dose strategy across partners takes repeated testing and know-how. That kind of network is imitation-resistant because small changes in dosing can shift safety and efficacy, so rivals can match the idea but not the execution.
Organization
Actinium Pharmaceuticals, Inc. keeps a tight transplant-first model, centering its network on one core area instead of spreading across broad oncology. That focus matters because its value depends on deep ties with transplant centers and partners around conditioning and targeted radiopharmaceutical work, not on a wide, low-conviction pipeline.
Competitive Advantage
Actinium Pharmaceuticals, Inc.'s multi-partner collaboration network gives it a temporary competitive advantage because it speeds trial access, shared know-how, and validation, but rivals can copy similar deals. In 2025, the Company still centered this model on 2 lead programs, Iomab-B and Actimab-A, so the edge depends on how fast it turns partner access into data and regulatory progress.
Actinium’s Partner Network Gives a Short-Term Trial Edge
Actinium Pharmaceuticals, Inc.'s multi-partner network is a narrow but useful asset: it helps run Iomab-B and Actimab-A through specialized transplant and radiopharma centers, speeding data flow and trial access. The edge is real but temporary, because similar partnerships can be copied once the clinical model is proven.
| Metric | 2025 |
|---|---|
| Lead programs | 2 |
| Network role | Trial access |
| Key risk | Copyable deals |
Intellectual property around proprietary constructs
Value
Actinium Pharmaceuticals, Inc.’s apamistamab platform has value because the Phase III SIERRA trial in 153 elderly relapsed/refractory AML patients targeted a narrow, high-unmet-need bridge-to-transplant niche before BMT, where few options exist. That IP can support clinical differentiation and pricing power if it keeps showing a clear transplant-access benefit versus standard care.
Rarity
Actinium Pharmaceuticals, Inc.’s multi-isotope construct know-how is rare for a small biopharma, since most peers focus on one radioisotope or one lead asset. That breadth can matter in IP because it gives the Company Name more ways to file, defend, and extend proprietary construct claims across different payloads and targets.
Imitability
Target choice can be copied, but Actinium Pharmaceuticals, Inc.’s construct-level optimization is harder to duplicate: each antibody-radionuclide pairing needs its own dose, schedule, and toxicity balance. In oncology, dose-finding often runs through 3 or more escalation cohorts, so the real IP edge sits in the empirical tuning, not just the target.
Organization
Actinium Pharmaceuticals, Inc. stays centered on transplant use cases, with a narrow portfolio built around Iomab-B and Actimab-A rather than broad oncology sprawl. That focus makes its proprietary constructs more valuable in VRIO terms because the IP is tied to a clear clinical niche, but the small scale also means any pipeline setback can hit the whole model hard.
Competitive Advantage
Actinium Pharmaceuticals, Inc. holds IP on its linker and antibody-radioisotope constructs, which can block copycats and support a temporary edge while patents and exclusivity last. But that edge is fragile in biotech: one trial setback or rival data can quickly erode it, and the value of the construct is tied to a small pipeline rather than a broad platform.
Actinium’s Rare IP Moat Faces Narrow Pipeline Risk
Actinium Pharmaceuticals, Inc.’s proprietary construct IP is valuable because its apamistamab platform was tested in the Phase III SIERRA trial in 153 elderly relapsed/refractory AML patients, proving a hard-to-copy transplant-bridge use case. The edge is rare and partly inimitable, but it stays fragile because a small pipeline means one setback can hit the whole IP story.
| Key data | Value |
|---|---|
| SIERRA Phase III patients | 153 |
| Core IP moat | Construct-level optimization |
| Risk | Narrow pipeline exposure |
Specialized isotope supply chain and handling
Value
Actinium Pharmaceuticals, Inc.’s specialized isotope supply chain and handling is valuable because I-131 apamistamab is in Phase III for elderly relapsed/refractory AML before BMT, a small but high-need niche with few direct alternatives. The asset’s clinical fit in a transplant-bridge setting supports clear medical value, while isotope logistics can be a real barrier that strengthens differentiation.
Rarity
Broad multi-isotope capability is rare for small biopharma firms, which usually focus on one lead radioisotope or partner for supply. Actinium Pharmaceuticals' work across multiple radiopharmaceutical programs makes its isotope handling know-how harder to copy, because supply, transport, and hot-cell processing add real operational friction.
Imitability
Target choice in Actinium Pharmaceuticals, Inc. can be copied, but the hard part is the isotope chain: Actinium-225 supply, radiolabeling, and dose calibration for each construct. That makes imitation weaker than it looks, because even small changes in isotope activity or dosing can alter safety and efficacy.
Organization
Actinium Pharmaceuticals, Inc. runs a narrow, transplant-first model: 1 late-stage transplant asset, Iomab-B, plus 1 myeloid program, Actimab-A, instead of a broad oncology slate. That focus makes its specialized actinium-225 supply and handling valuable, because Ac-225 has a 10-day half-life and needs tight chain control.
Competitive Advantage
Actinium Pharmaceuticals, Inc. has a niche edge in handling actinium-225 and other radiopharma inputs, where a 10-day half-life and tight cold-chain rules make sourcing and logistics hard to copy. That edge can support a temporary competitive advantage, but it is not durable because isotope supply is still scarce and more producers can enter the market.
Actinium’s Isotope Supply Chain Creates a Real, But Temporary, Moat
Actinium Pharmaceuticals, Inc.’s isotope chain is valuable because Ac-225’s 10-day half-life makes sourcing, transport, and dose control hard to copy. That handling know-how supports Iomab-B and Actimab-A, but the edge is only partly rare because isotope supply can expand.
| Key item | Value |
|---|---|
| Ac-225 half-life | 10 days |
| Lead late-stage asset | Iomab-B Phase III |
So the supply chain adds real friction, but it is more of a temporary moat than a permanent one.
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.